Trial Profile
A Two-Part, Open-label, Sequential, Double Cohort, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Rosuvastatin When Co Administered With Darapladib in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Darapladib (Primary) ; Rosuvastatin (Primary)
- Indications Atherosclerosis; Cardiovascular disorders; Diabetic macular oedema; Hypercholesterolaemia; Hyperlipidaemia; Hypertriglyceridaemia
- Focus Pharmacokinetics
- Sponsors GSK
- 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jan 2013 New trial record
- 01 Dec 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.